Personalized medicine

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

Retrieved on: 
星期四, 十一月 9, 2023
Research, Bayer, IND, Clostridioides difficile infection, Ovarian cancer, Hemangioma, FAP, Therapy, H100, Foundation models, Genetics, PB, SALT, Exercise, Software, Development, NF2, Pharmacokinetics, APC, NVIDIA, Clinical trial, Biology, Drug discovery, CCM, Partnership, Machine learning, Recursion, Meningioma, Personalized medicine, Benchmarking, LILAC, AXIN1, Genentech, Safety, Chemistry, Patient, Biotechnology, Map, Administration, Video game, Pharmaceutical industry, Fine chemical, Tempus

Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $29.2 million for the third quarter of 2023, compared to $19.5 million for the third quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the third quarter of 2023, compared to a net loss of $60.4 million for the third quarter of 2022.
  • Net Cash: Net cash used in operating activities was $72.9 million for the third quarter of 2023, compared to net cash used in operating activities of $54.5 million for the third quarter of 2022.

Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials.

Retrieved on: 
星期三, 十一月 8, 2023
Science, FDA, Biomarker, Clinical trial, Marie Cassidy, Pathology, Fibrosis, Organization, Phenotype, Artificial intelligence, Drug development, Soft tissue injury, Disease, NASH, Medicine, Ecosystem, Partnership, Personalized medicine, Digital pathology, Patient, Doctor of Philosophy, Fatty liver disease, Medical imaging

By harnessing the collective expertise of Alimentiv, AcelaBio, and PharmaNest, this collaboration will establish an integrated ecosystem that seamlessly combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis.

Key Points: 
  • By harnessing the collective expertise of Alimentiv, AcelaBio, and PharmaNest, this collaboration will establish an integrated ecosystem that seamlessly combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis.
  • AcelaBio, a CAP/CLIA-certified clinical research laboratory known for its end-to-end digital pathology workflows, will carry out tissue sample analysis to generate whole slide images and molecular data.
  • Our Fibrosis Digital Pathology biomarker, Ph-FCS, offers exceptional performance as a diagnostic tool for early and severe fibrosis.
  • The collaboration between Alimentiv, AcelaBio, and PharmaNest represents a substantial leap forward in integrating precision medicine and digital pathology solutions for MASH clinical trials.

Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials.

Retrieved on: 
星期三, 十一月 8, 2023
Science, FDA, Biomarker, Clinical trial, Marie Cassidy, Pathology, Fibrosis, Organization, Phenotype, Artificial intelligence, Drug development, Soft tissue injury, Disease, NASH, Medicine, Ecosystem, Partnership, Personalized medicine, Digital pathology, Patient, Doctor of Philosophy, Fatty liver disease, Medical imaging

By harnessing the collective expertise of Alimentiv, AcelaBio, and PharmaNest, this collaboration will establish an integrated ecosystem that seamlessly combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis.

Key Points: 
  • By harnessing the collective expertise of Alimentiv, AcelaBio, and PharmaNest, this collaboration will establish an integrated ecosystem that seamlessly combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis.
  • AcelaBio, a CAP/CLIA-certified clinical research laboratory known for its end-to-end digital pathology workflows, will carry out tissue sample analysis to generate whole slide images and molecular data.
  • Our Fibrosis Digital Pathology biomarker, Ph-FCS, offers exceptional performance as a diagnostic tool for early and severe fibrosis.
  • The collaboration between Alimentiv, AcelaBio, and PharmaNest represents a substantial leap forward in integrating precision medicine and digital pathology solutions for MASH clinical trials.

BostonGene and Weill Cornell Medicine to Showcase Poster Presentations on Transcriptome-based Tumor Microenvironment Classification for Advancement of Personalized Cancer Therapeutics at the 20th International Cancer Genome Consortium Scientific...

Retrieved on: 
星期二, 十一月 7, 2023
Biotechnology, Health, Oncology, Research, GBM, International Cancer Genome Consortium, Prostate cancer, ARGO, RNA-Seq, Neoplasm, Cancer, Personalized medicine, ICGC, Classification, Tumor microenvironment, TME, Patient, Weill Cornell Medicine, Glioblastoma, Gene expression, Metastasis, Medical imaging

Details of the presentations are as follows:

Key Points: 
  • Details of the presentations are as follows:
    Metastatic castration-resistant prostate cancer (mCRPC) that is not dependent on the androgen receptor accounts for approximately 25-30% of fatal prostate cancer cases.
  • In this study, BostonGene's transcriptome-based tumor microenvironment (TME) classification approach identified five previously unidentified subtypes in both a meta-cohort and an independent cohort.
  • Understanding tumor heterogeneity is critical to improve cancer therapies in glioblastoma (GBM), the most common primary brain cancer in adults.
  • Click here to learn more about the 20th International Cancer Genome Consortium Scientific Workshop/ 7th Accelerating Research in Genomic Oncology (ARGO) meeting.

RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration

Retrieved on: 
星期一, 十月 30, 2023
Biomarker, Ophthalmology, Institutional review board, Intravitreal injection, Hematology, AMD, BrightFocus Foundation, MD, Research, Anti-VEGF, OTCQB, JAMA Ophthalmology, News, Disease, University, Personalized medicine, Blood, Safety, Patient, Pharmaceutical industry

The study aims to offer recommendations for enhancing the preselection process and management of ocular injections.

Key Points: 
  • The study aims to offer recommendations for enhancing the preselection process and management of ocular injections.
  • The proposed patient selection process has the potential to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections.
  • “RetinalGeniX DNA/GPS has submitted a study with Pearl IRB to perform a clinical review of 390 patients.
  • Jerry Katzman, MD, the CEO of RetinalGeniX, emphasized the importance of limiting ocular anti-VEGF injections into patients’ eyes for those who are good candidates for responsive treatment.

South Africa Biopharmaceuticals Market Outlook & Forecast Report 2023-2028: Push for Local Biopharmaceutical Production Attracts Global Interest - ResearchAndMarkets.com

Retrieved on: 
星期一, 十一月 6, 2023
Biotechnology, Pharmaceutical, Health, WHO, Anthrax Vaccine Immunization Program, Biomedical Research, Ageing, Strategic planning, Rare, Vaccine, Therapy, Prevalence, Conditional sentence, Research, ART, Quality of life, Growth, Life expectancy, A-DNA, Personalized medicine, Medicine, HIV/AIDS, Economic development, Hormone, Infection, Public, Patient, Fine chemical, Pharmaceutical industry, Health care, African

The "South Africa Biopharmaceuticals Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "South Africa Biopharmaceuticals Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • South Africa is showing promising signs of local biopharmaceutical production, reflecting a strong interest in developing a self-sufficient pharmaceutical industry.
  • Promoting local production in the South Africa biopharmaceuticals market can enhance access to essential medicines, drive healthcare innovation, and contribute to economic development, ultimately benefiting the healthcare sector and the population's well-being.
  • The growing South Africa biopharmaceuticals market offers attractive investment opportunities for companies and investors.

Labroots Announces Agenda for its 14th Annual Clinical Diagnostics & Research Online Event - held on November 8th, 2023

Retrieved on: 
星期一, 十一月 6, 2023
Linda, TBI, Q&A, Pathology, Medical laboratory, Clinical professor, Workplace, Research, Sartorius, Dietary supplement, Mass spectrometry, Ortho Clinical Diagnostics, Roche, Networking hardware, Medicine, Labroots, Greeting, LR, Personalized medicine, Melissa Chaty, Thermo Fisher Scientific, Diversity, Lab, Patient, Mayo Clinic, Medical device, Nursing, News, Clinical

YORBA LINDA, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 14th annual event in the Clinical Diagnostics & Research Virtual Event Series scheduled on November 8, 2023. This event will continue its long-standing commitment to advance clinical diagnostics, novel research and medicine, and to align research scholars, clinicians, top scientists, healthcare professionals and experts from leading academia and industry institutions under a virtual roof on a global basis.

Key Points: 
  • YORBA LINDA, Calif., Nov. 6, 2023 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 14th annual event in the Clinical Diagnostics & Research Virtual Event Series scheduled on November 8, 2023.
  • Attendees will also see multiple panels and presentations from key industry sponsors including, Sartorius, Thermo Fisher Scientific, and Roche Diagnostics.
  • Use the hashtag #LRclinical to follow the conversation and connect with other members of the global Clinical & Molecular Dx Community!
  • Join our Clinical & Molecular Dx Interest Group on LinkedIn to connect with us, and the wider professional community!

How AI is Transforming Drug Discovery: Bio-IT World Europe Participants to Share Groundbreaking Advances 29-30 November in London

Retrieved on: 
星期一, 十一月 6, 2023
Digital, China Earthquake Networks Center, AstraZeneca, Expert system, Health care, Government, LDN, Conference, Organization, Research, Drug development, Clarivate, Artificial intelligence, MOSAIC, Medicine, Drug discovery, Machine learning, Personalized medicine, RDN, AI, Potential, D, Queen Mary University of London, Medical device, Cancer

LONDON, Nov. 6, 2023 /PRNewswire-PRWeb/ -- The life sciences profession is in the midst of a profound transformation, guided by the revolutionary force of artificial intelligence (AI), and especially predictive and generative AI models. These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.

Key Points: 
  • These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.
  • "The bio-IT community has always been at the forefront of leveraging AI with the important goal of increasing therapeutic efficacy."
  • In parallel, generative AI refines molecular design with exquisite precision, drastically curtailing the time and resources necessary for drug development.
  • "As general interest in AI explodes, our distinguished speakers have valuable information to share about its evolving role in precision medicine."

Dynami Funds New Groundbreaking Research for Lobular Breast Cancer

Retrieved on: 
星期三, 十一月 1, 2023
Dean (education), Karmanos Cancer Institute, Biomarker, Leigh, Doctor of Philosophy, Disease, Risk, Partnership, DRS, University of Michigan, UPMC, Fertility preservation, Hope, Physician, Hereditary lobular breast cancer, Impact, University of Pittsburgh Medical Center, IVF, Breast cancer, University, Morávek, Cancer, Patient, Biomedical engineering, ILC, University of Colorado, History, MD, Work, Woman, University of Colorado School of Medicine, Black, Multimedia, Recurrence, Personalized medicine, United States and Canadian Academy of Pathology, Medical device, Vaccine, Medical imaging, Birth control, Pharmaceutical industry, Research, Pathology, Pharmacology, Dynamy

DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health. Recently released University of Michigan Health Impact Report outlines the progress and work made possible by the Dynami Foundation's initiatives that are focused on transforming the future of invasive lobular breast cancer (ILC) through the funding of research.

Key Points: 
  • DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health.
  • From groundbreaking new research on circulating cells to a dual-institution effort to combat cancer, Dynami and University of Michigan have partnered to drive progress.
  • A patient-centered decision-making process by understanding goals of lobular breast cancer patients for an elevated, personalized breast reconstruction experience led by Dr. Paige Myers.
  • Dynami has funded over 12 research projects and will continue to fight for advancement for lobular breast cancer just like the incredible work and impact that we've made here."

LUNGevity Foundation's No One Missed Campaign Commemorates Third Year of #KnowYourBiomarker Storytelling Initiative

Retrieved on: 
星期三, 十一月 1, 2023
Aurora, Insurance, NSCLC, Cancer Support Community, Lung cancer, Wellstar Health System, Organization, Hope, Northside Hospital, ALK, Research, Progress, Chest pain, Disease, Winship Cancer Institute, NED, Radiation, Emory University, Biopsy, CT, X-ray, Immunotherapy, Personalized medicine, Fertility preservation, Cancer, Patient, Diagnosis, Prognosis, Mutation, EGFR, Medical imaging, Atlanta

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit, today celebrates the third year of #KnowYourBiomarker, a social media initiative that highlights the stories of people living well with lung cancer. The initiative is part of LUNGevity's No One Missed campaign aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).

Key Points: 
  • She started chemotherapy, which resulted in awful side effects that prevented her from being able to work.
  • After her healthcare team ordered biomarker testing, they discovered her cancer was positive for the ALK mutation and matched Shirley with a targeted therapy.
  • Now, three years after her diagnosis, Shirley is living her life to the fullest.
  • In addition to No One Missed's #KnowYourBiomarker initiative, LUNGevity has other ways to get involved during Lung Cancer Awareness Month.